Showing results (11-20 of 35) with videos related to
Sort By:
Pageof 4
American Journal of Therapeutics|May 17, 2014
Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy SubjectsBrett Lauring, Victor Dishy, Pieter-Jan De Kam, et al.Journal of Clinical Pharmacology|March 4, 2010
Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjectsFang Liu, Laura Vessey, Larissa Wenning, et al.CPT: Pharmacometrics & Systems Pharmacology|June 20, 2019
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal DosingJos Lommerse, Diana Clarke, Thomas Kerbusch, et al.CPT: Pharmacometrics & Systems Pharmacology|May 30, 2024
Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertensionSihem Ait-Oudhia, David Jaworowicz, Ziheng Hu, et al.Platelets|November 12, 2013
The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirinPieter-Jan De Kam, Wen-Lin Luo, Larissa Wenning, et al.Clinical Pharmacology and Therapeutics|July 16, 2022
Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated AnalysisMaria E Trujillo, Leticia Arrington, Yogesh Patel, et al.Antimicrobial Agents and Chemotherapy|March 21, 2012
Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patientsMatthew L Rizk, Yaming Hang, Wen-Lin Luo, et al.Molecular Pharmaceutics|December 18, 2019
ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ ConsortiumPhilip Bransford, Jack Cook, Manish Gupta, et al.Clinical Pharmacology and Therapeutics|December 13, 2024
Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling Analyses of Sotatercept in Healthy Participants and Patients with Pulmonary Arterial HypertensionSihem Ait-Oudhia, David Jaworowicz, Ziheng Hu, et al.European Journal of Clinical Pharmacology|January 26, 2019
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairmentLuzelena Caro, Larissa Wenning, Hwa-Ping Feng, et al.Pageof 4